Lixte Biotechnology Holdings, Inc. Warrants (LIXTW)
Company News
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
LIXTE Biotechnology is advancing its cancer therapy pipeline with LB-100, a protein phosphatase 2A inhibitor targeting ovarian clear cell carcinoma, soft tissue sarcoma, and metastatic colon cancer, with potential trial results expected in late 2025.